No Data
No Data
Shares of US-listed Chinese Companies Are Trading Higher Amid Overall Market Strength After the United States and China Temporarily Suspended Most Tariffs on Each Other's Goods.
Sino-U.S. talks bring warmth! The financial markets welcome "Mad Monday," with Hong Kong stocks rising above 23,000 points, and Pre-Market Trading skyrocketing across the board.
This high-level economic and trade dialogue between China and the United States has achieved substantial progress, significantly reducing bilateral tariff levels. The U.S. has canceled a total of 91% of the additional tariffs, and China has correspondingly canceled 91% of the counter-tariffs; the U.S. has suspended the implementation of a 24% "reciprocal tariff," and China has also correspondingly suspended the implementation of a 24% counter-tariff.
Three sentences to analyze the "substantial progress" in the high-level China-U.S. economic and trade talks.
Local time from May 10 to 11, high-level economic and trade talks between China and the United States were held in Geneva, Swiss Franc. The talks reached a series of important consensus and achieved substantial progress.
The "Seven Giants" are making a comeback; can technology stocks still be purchased? The direction of the U.S. stock market is subtly changing!
After a brutal correction in April, the technology giants have strongly rebounded, driving a recovery in the US stock market in May. However, amid the lingering shadow of Trump's tariff policies and uncertainties regarding the economic outlook, investors are facing tough choices.
The Ministry of Commerce: China and the United States have canceled a total of 91% of the additional tariffs and suspended the implementation of 24% of the counter tariffs.
This high-level economic and trade dialogue between China and the United States has achieved substantial progress, significantly reducing bilateral tariff levels. The U.S. has canceled a total of 91% of the additional tariffs, and China has correspondingly canceled 91% of the counter-tariffs; the U.S. has suspended the implementation of a 24% "reciprocal tariff," and China has also correspondingly suspended the implementation of a 24% counter-tariff.
VIS---In the first quarter, collaborative drug development research with each partner is progressing as planned, but there is a deficit.
Veritas In Silico <130A> announced its financial results for the first quarter of the fiscal year ending December 2025 (January-March 2025) on the 9th. Business revenue was 0.024 billion yen, down 25.0% compared to the same period last year, with an operating loss of 0.081 billion yen (compared to a loss of 0.065 billion yen in the same period last year), an ordinary loss of 0.079 billion yen (compared to a loss of 0.087 billion yen last year), and a quarterly net loss of 0.079 billion yen (compared to a loss of 0.087 billion yen last year). In the company's mRNA-targeted small molecule drug discovery business, the drug discovery platform